STOCK TITAN
  1. Home
  2. Sec-filings
  3. PROF
  4. [8-K] Profound Medical Corp. Reports Material Event

Profound Medical (NASDAQ: PROF) to report Q1 2026 results, host call May 7

Filing Impact
(Moderate)
Filing Sentiment
(Neutral)
Form Type
8-K

Rhea-AI Filing Summary

Profound Medical Corp. announced it will release its first quarter 2026 financial results after market close on Thursday, May 7, 2026, and host a conference call at 4:30 p.m. Eastern Time that day to review the results and discuss business developments.

The company is a commercial-stage medical device business focused on AI-powered, MRI-guided, incision-free therapies. Its flagship TULSA-PRO platform supports MRI-guided prostate therapy, while Sonalleve provides non-surgical, MRI-guided treatments for bone metastases, certain tumors, and gynecologic conditions.

Positive

  • None.

Negative

  • None.
Item 7.01 Regulation FD Disclosure Disclosure
Material non-public information disclosed under Regulation Fair Disclosure, often investor presentations or guidance.
Item 9.01 Financial Statements and Exhibits Exhibits
Financial statements, pro forma financial information, and exhibit attachments filed with this report.
Results release date May 7, 2026 First quarter 2026 financial results to be released after market close
Conference call time 4:30 p.m. Eastern Time Call to review first quarter 2026 results on May 7, 2026
North America dial-in 1-800-717-1738 Live conference call access number for North American participants
International dial-in 1-646-307-1865 Live conference call access number for international participants
Press release date April 16, 2026 Date of press release announcing Q1 2026 results timing
Regulation FD Disclosure regulatory
"Item 7.01. Regulation FD Disclosure."
emerging growth company regulatory
"Emerging growth company"
An emerging growth company is a recently public or smaller public firm that qualifies for temporary, lighter regulatory and disclosure rules to reduce the cost and effort of being public. For investors, it means the company may provide less historical financial detail and face fewer reporting requirements than larger firms, so it can grow more quickly but also carries higher uncertainty—like buying a promising early-stage product with fewer user reviews.
MRI-guided medical
"an innovator in interventional MRI procedures, enabling precise, incision-free therapies"
MRI-guided describes medical procedures or devices that use real-time magnetic resonance imaging to visualize internal anatomy and steer instruments, implants, or therapeutic energy precisely to a target. For investors, MRI-guided technology can signal higher potential value because it may improve treatment accuracy, reduce complications and recovery time, and enable premium pricing or clearer regulatory paths—like using GPS instead of a paper map to reach a hard-to-find location.
TULSA-PRO medical
"The company’s flagship platform, TULSA-PRO®, enables MRI-guided, incision-free prostate therapy"
Sonalleve medical
"Profound also commercializes Sonalleve®, an MRI-guided therapy that provides a non-surgical treatment option"
Understanding 8-K Material Events →
False000162880800016288082026-04-162026-04-16iso4217:USDxbrli:sharesiso4217:USDxbrli:shares
 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

_________________

FORM 8-K

_________________

CURRENT REPORT

Pursuant to Section 13 or 15(d)
of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported):  April 16, 2026

_______________________________

PROFOUND MEDICAL CORP.

(Exact name of registrant as specified in its charter)

_______________________________

Ontario, Canada001-39032Not Applicable
(State or Other Jurisdiction of Incorporation)(Commission File Number)(I.R.S. Employer Identification No.)

2400 Skymark Avenue, Unit 6

Mississauga, Ontario, Canada L4W 5K5

(Address of Principal Executive Offices) (Zip Code)

Registrant's Telephone Number, Including Area Code: 647-476-1350

 

 

(Former name or former address, if changed since last report)

_______________________________

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each classTrading Symbol(s)Name of each exchange on which registered
Common SharesPROFThe Nasdaq Stock Market

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

 
 
Item 7.01. Regulation FD Disclosure.

 

On April 16, 2026, Profound Medical Corp. (the “Company”) issued a press release announcing that it plans to release its first quarter 2026 financial results after market close on Thursday, May 7, 2026, and that the Company will host a conference call to review the financial results and discuss business developments at 4:30 p.m. Eastern Time on the same day. The press release contains additional information regarding how to access the conference call and webcast. A copy of the press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K.

 

The information furnished under this Item 7.01, including Exhibit 99.1, shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, or the Exchange Act, or subject to the liabilities of that section or Sections 11 and 12(a)(2) of the Securities Act of 1933, or the Securities Act. The information in this Item 7.01, including Exhibit 99.1, shall not be deemed incorporated by reference into any other filing with the U.S. Securities Exchange Commission, or the SEC, made by the Company, whether made before or after the date hereof, regardless of any general incorporation language in such filing.

 

Item 9.01. Financial Statements and Exhibits.

 

(d) Exhibits

 

Exhibit No.Description
99.1Press Release, dated April 16, 2026
104Cover Page Interactive Data File (embedded within Inline XBRL document)

 

 
 

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 PROFOUND MEDICAL CORP.
   
  
Date: April 16, 2026By: /s/ Rashed Dewan        
  Rashed Dewan
  Chief Financial Officer
  

 

EXHIBIT 99.1

Profound Medical to Release First Quarter 2026 Financial Results on May 7 – Conference Call to Follow

TORONTO, April 16, 2026 (GLOBE NEWSWIRE) -- Profound Medical Corp. (NASDAQ:PROF; TSX:PRN) (“Profound” or the “Company”), a commercial-stage medical device company that develops and markets AI-powered, MRI-guided, incision-free therapies for the ablation of diseased tissue, will announce its first quarter 2026 financial results after market close on Thursday, May 7, 2026.

Profound management will host a conference call at 4:30 p.m. ET to review the financial results and discuss business developments in the period.

First Quarter 2026 Results Conference Call Details:

Date: Thursday, May 7, 2026

Time: 4:30 p.m. ET

Live Call Dial-in Numbers: 1-800-717-1738 (North America) or 1-646-307-1865 (International)

The call will also be broadcast live and archived here.

About Profound Medical Corp.

Profound is a commercial-stage medical device company and an innovator in interventional MRI procedures, enabling precise, incision-free therapies that improve clinical confidence, procedural control, and patient outcomes. By leveraging real-time MRI guidance, Profound’s technologies are designed to replace uncertainty with clarity across treatment planning, delivery, and confirmation.

The company’s flagship platform, TULSA-PRO®, enables MRI-guided, incision-free prostate therapy designed for precision and flexibility. The TULSA Procedure™ allows physicians to see, treat, and confirm therapy in real time, supporting personalized treatment strategies across the continuum of prostate care—from whole-gland to subtotal, hemi, multifocal, and focal treatment. This approach enables individualized care for the full spectrum of prostate disease, including prostate cancer and/or benign prostatic hyperplasia (BPH), while minimizing side effects typically associated with surgery or radiation, such as urinary incontinence and/or erectile dysfunction.

Profound also commercializes Sonalleve®, an MRI-guided therapy that provides a non-surgical treatment option for pain palliation of bone metastases, desmoid tumors, and osteoid osteoma, as well as for common gynecologic conditions including uterine fibroids and adenomyosis. Sonalleve delivers targeted therapy with no incisions, no blood loss during the procedure, no overnight hospital stay, and faster recovery — and, in gynecologic applications, enables uterine-sparing treatment that may help preserve fertility. Profound is also exploring additional clinical applications for Sonalleve, including non-invasive ablation of abdominal cancers and hyperthermia-based cancer therapies.

Profound Medical’s technologies are approved across major global markets. TULSA-PRO is cleared or approved in the United States, Europe, Canada, Saudi Arabia, India, Australia/New Zealand, and the UAE, while Sonalleve is cleared or approved in the United States (HDE), Europe, Canada, China, and Saudi Arabia.

Through real-time MRI guidance and data-driven innovation, Profound is advancing the future of MRI-guided therapy — expanding access to precise, personalized, and incision-free treatment options worldwide.

For further information, please contact:

Stephen Kilmer
Investor Relations
skilmer@profoundmedical.com
T: 647.872.4849

Source: View Original Filing on SEC EDGAR

FAQ

What does Profound Medical Corp. (PROF) announce in this 8-K filing?

Profound Medical Corp. announces plans to release its first quarter 2026 financial results after market close on May 7, 2026, and to host a same-day conference call discussing results and business developments, with access details provided in an attached press release.

When will Profound Medical (PROF) report its first quarter 2026 financial results?

Profound Medical plans to announce its first quarter 2026 financial results after market close on Thursday, May 7, 2026. Management will then host a conference call at 4:30 p.m. Eastern Time that same day to review results and discuss business developments.

How can investors join Profound Medical’s May 7, 2026 earnings conference call?

Investors can join the live call by dialing 1-800-717-1738 in North America or 1-646-307-1865 internationally at 4:30 p.m. ET on May 7, 2026. The call will also be broadcast live and archived via an online webcast link referenced in the release.

What type of company is Profound Medical Corp. (PROF)?

Profound Medical is a commercial-stage medical device company specializing in AI-powered, MRI-guided, incision-free therapies for ablating diseased tissue. Its technologies aim to improve clinical confidence, procedural control, and patient outcomes through real-time MRI guidance across planning, delivery, and confirmation of treatment.

What is Profound Medical’s TULSA-PRO platform and what conditions does it target?

TULSA-PRO is Profound Medical’s flagship MRI-guided, incision-free prostate therapy platform. The TULSA Procedure lets physicians see, treat, and confirm therapy in real time, supporting personalized treatment for prostate disease, including prostate cancer and benign prostatic hyperplasia, while aiming to minimize side effects like incontinence and erectile dysfunction.

What conditions can Profound Medical’s Sonalleve system treat?

Sonalleve is an MRI-guided therapy system offering non-surgical treatment for pain palliation of bone metastases, desmoid tumors, and osteoid osteoma, plus gynecologic conditions such as uterine fibroids and adenomyosis. It delivers targeted, incision-free therapy with no blood loss and typically no overnight hospital stay, supporting uterine-sparing options.

Filing Exhibits & Attachments

5 documents

Press Releases

Other Documents